What is Cytokinetics's derivative liability, current?

Cytokinetics (CYTK) reported derivative liability, current of $29.6M in Q1 2026.

How has Cytokinetics's derivative liability, current changed year-over-year?

Cytokinetics's derivative liability, current increased by 153.0% year-over-year, from $11.7M to $29.6M.

Cytokinetics CYTK Derivative Liability, Current

Derivative Liability, Current at other companies

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

See full

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

See full

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

See full

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

See full

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

See full

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's derivative liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytokinetics's derivative liability, current?: Cytokinetics (CYTK) reported derivative liability, current of $29.6M in Q1 2026.
How has Cytokinetics's derivative liability, current changed year-over-year?: Cytokinetics's derivative liability, current increased by 153.0% year-over-year, from $11.7M to $29.6M.